Two ongoing studies, HIGHLIGHT 1 and OPTION-VMS, include patients with breast cancer, but most of these patients were excluded in earlier trials.
Medical history in SKYLIGHT studies5
Table 1. Medical history of breast cancer in SKYLIGHT 1 and 2 (12-week pre-specified analysis) (Full Analysis Seta)5
Category/Condition | Placebo (n = 342) | Fezolinetant 30 mg (n = 339) | Fezolinetant 45 mg (n = 341) |
|---|---|---|---|
Family history of breast cancer in first degree relative or mutation of breast cancer gene (BRCA 1 and 2) | 12 (3.5%) | 8 (2.4%) | 6 (1.8%) |
aFAS: All randomized participants assessed according to the randomization at first dose.
Table 2. Family history of breast cancer in SKYLIGHT 4 (52-week safety study) (Safety Analysis Seta)5
Hormone Replacement Therapy Status/Category | Placebo (n = 610) | Fezolinetant 30 mg (n = 611) | Fezolinetant 45 mg (n = 609) |
|---|---|---|---|
Family history of breast cancer | 29 (4.8%) | 22 (3.6%) | 20 (3.2%) |
aSAF: All randomized participants who took at least one dose of study intervention.
Medical history in the DAYLIGHT study5
Table 3. Family history of breast cancer in DAYLIGHT (24-week study) (Safety Analysis Seta)5
Parameter | Placebo (n = 226) | Fezolinetant 45 mg (n = 226) |
|---|---|---|
Family history of breast cancer in first degree relative or mutation of breast cancer gene (BRCA 1 or 2) | 42 (18.6%) | 40 (17.7%) |
Relationship to participant | Relationship to participant | Relationship to participant |
Relative, first degree | 2 (4.8%) | 1 (2.5%) |
Mother, biological | 24 (57.1%) | 17 (42.5%) |
Sister, full | 9 (21.4%) | 8 (20.0%) |
Child, biological | 1 (2.4%) | 1 (2.5%) |
Grandmother, biological | 3 (7.1%) | 6 (15.0%) |
Aunt, biological | 10 (23.8%) | 12 (30.0%) |
aSAF: All randomized participants who received at least one dose of study drug.
Ongoing clinical trials
Phase 3 study - HIGHLIGHT 1 (NCT06440967)5,6
Phase 4 study - OPTION-VMS (NCT06049797)7,8
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. Available at: https://doi.org/10.1016/s0140-6736(23)00085-5.
Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J. Clin. Endocrinol. Metab. 2023;108(8):1981-1997. Available at: https://doi.org/10.1210/clinem/dgad058.
Neal-Perry G, Cano A, Lederman S, et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause. Obstet. Gynecol. 2023;141(4):737-747. Available at: https://doi.org/10.1097/aog.0000000000005114.
Schaudig K, Wang X, Bouchard C, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024;387(387):e079525. Available at: https://doi.org/10.1136/bmj-2024-079525.
Data on file.
Bouchard C, Miyazaki K, Tang CH, et al. Trial in Progress: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate-to-severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy [abstract].
Neal-Perry G, Lederman S, Mancuso S, et al. OPTION-VMS: Preliminary Analysis of a Phase IV Observational, Real-World Study of Non-hormonal Pharmacotherapies for Bothersome Menopause-Associated Vasomotor Symptoms [poster]. The Menopause Society (TMS) 2025 Annual Meeting. Orlando, FL, USA. 2025.
Maki PM, Mancuso S, Helbing M, et al. Preliminary Analysis of Work Productivity Outcomes in OPTION-VMS: A Phase IV Observational, Real-World Study of Non-hormonal Treatment for Bothersome Menopause-Associated Vasomotor Symptoms [poster]. The Menopause Society (TMS) 2025 Annual Meeting. Orlando, FL, USA. 2025.
If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here